💊 의약품 A-Z 🧬 표적 🛠 도구 📚 가이드
전체 의약품 약물 분류 치료 영역 부작용
가이드 용어집 연대표
비교 약물 체내 여정 약물 계열
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Gentamicin

CHEMBL6067485 Phase 4 승인됨 Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
477.6 g/mol
LogP
-4.1
Phase
4

An aminoglycoside antibiotic used to treat serious bacterial infections caused by gram-negative organisms, including infections of the respiratory tract, urinary tract, bloodstream, and other sites. It works by binding to bacterial ribosomes and inhibiting protein synthesis, leading to bacterial cell death. Due to risks of kidney damage and hearing loss, blood levels and kidney function require careful monitoring during treatment.

분자량

477.6000 g/mol

LogP

-4.10

TPSA

200.00 Ų

리핀스키 5의 법칙

불통과

치료 영역

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Glaucoma Pain Management Non-Small Cell Lung Cancer Rheumatoid Arthritis Osteoporosis Infectious Disease Obesity Type 2 Diabetes Breast Cancer Atopic Dermatitis Chronic Pain Malaria HIV/AIDS Tuberculosis Prostate Cancer Colorectal Cancer

작용 기전

Binds irreversibly to the 30S ribosomal subunit, causing misreading of mRNA codons and inhibition of translocation. This leads to production of aberrant proteins and disruption of the bacterial cell membrane.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

기전

Binds irreversibly to the 30S ribosomal subunit, causing misreading of mRNA codons and inhibition of translocation. This leads to production of aberrant proteins and disruption of the bacterial cell membrane.

2D 구조

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
CC(C1CCC(C(O1)OC2C(CC(C(C2O)OC3C(C(C(CO3)(C)O)NC)O)N)N)N)NC

                

                

                
                

                    
InChI

                    
InChI=1S/C21H43N5O7/c1-9(25-3)13-6-5-10(22)19(31-13)32-16-11(23)7-12(24)17(14(16)27)33-20-15(28)18(26-4)21(2,29)8-30-20/h9-20,25-29H,5-8,22-24H2,1-4H3

                

                

                

                    
                    

                        
Molecular Formula

                        
C21H43N5O7

                    

                    
                    

                        
HBD / HBA

                        
8 / 12

                    

                    
                    

                        
회전 가능 결합

                        
7

                    

                    
                    
                    

                        
무거운 원자

                        
33

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
자주 묻는 질문

                

                    
                    

                        
                        

                            
An aminoglycoside antibiotic used to treat serious bacterial infections caused by gram-negative organisms, including infections of the respiratory tract, urinary tract, bloodstream, and other sites. It works by binding to bacterial ribosomes and inhibiting protein synthesis, leading to bacterial cell death. Due to risks of kidney damage and hearing loss, blood levels and kidney function require careful monitoring during treatment.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Binds irreversibly to the 30S ribosomal subunit, causing misreading of mRNA codons and inhibition of translocation. This leads to production of aberrant proteins and disruption of the bacterial cell membrane.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Gentamicin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL6067485.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 3467.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.




        


        
        
    


    



    
의학적 면책조항

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.